Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Both face headwinds -- and future opportunities.

Better Buy: Viatris vs. AbbVie

PITTSBURGH, Dec. 17, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that it will move its investor event previously scheduled for Friday, January 7, 2022 to no later than February 28, 2022 in conjunction with the release of its fourth quarter 2021 results. The Company also reiterated its 2021 financial guidance, previously provided on November 8, 2021.

Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results

Preferred Apartment Communities

Johnson & Johnson

Kinder Morgan

PepsiCo

Pfizer

Provident Financial Services

Procter & Gamble

STORE Capital

Vanguard High Dividend Yield ETF

Exxon Mobil

I invested quite a bit into the VYM ETF. This has helped me amass an investment with Vanguard of over $40,000+ since last year!

Dividend Stock Purchase: Lanny's November 2021 Summary

Best Buy

BorgWarner

Altria

Smith & Wesson Brands

ViacomCBS

Western Union

Value stocks are not always winners. That's on full display with the scores of "value traps" that leave investors with big regret and poor performance.

7 of the Best Value Stocks for 2022 to Buy Now

Amgen

Bristol-Myers

Conagra Brands

Campbell Soup

Merck

AT&T

Verizon

Above-average yields alone aren't enough of a reason to start buying.

Is It Time to Buy the 8 Worst-Performing Dividend Stocks of 2021?

Investors looking to take advantage of the large and rapidly growing market for biosimilar drugs might want to keep an eye on a potential deal cooking between the Pfizer Inc. ( PFE , Financial) spinoff Viatris Inc. ( VTRS , Financial) and an Indian biosimilar company called Biocon Limited (BIOCON.NS).

Will Adding Viatris Help Unlock the Value in Biocon?

Viatris Inc. is a pharmaceutical company formed through the merger between Mylan and Upjohn, a division of Pfizer (PFE), on 16 November 2020.

Viatris Stock: A Potential Cash Cow At An Attractive Entry Point

Viatris is down 30% since I rated it as a buy. The fundamentals have not changed, and the company is revising its guidance upward.

Viatris Is A Strong Buy

PITTSBURGH, Dec. 6, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a new kind of global healthcare company, today announced that Newsweek has named the company to its list of America's Most Responsible Companies 2022. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider.

Viatris Named by Newsweek as One of America's Most Responsible Companies

Annaly Capital

Rising quarterly payouts and above-average yields make these dividend stocks worthy of your immediate attention.

3 Beaten-Down Dividend Stocks -- Are They Bargins Now?

Evercore

Viatris Inc. (VTRS) CEO Michael Goettler Presents at 4th Annual Evercore ISI HealthCONx Virtual Brokers Conference (Transcript)

PITTSBURGH, Dec. 1, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogen's Tecfidera® patent, U.S. Patent No. 8,399,514, for lack of written description.

Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent

AstraZeneca

Horizon Pharma

Novartis

Vertex Pharmaceuticals

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. The post 7 Drug Stocks to Buy Now While They're Still on Sale appeared first on InvestorPlace.

7 Drug Stocks to Buy Now While They're Still on Sale

It's not too late if you're looking for dividend income.

Is It Too Late to Buy Viatris Stock?

American Electric Power Company

Aflac

Cummins

Realty Income Corp

The stock market, specifically the S&P 500, still is high, but is down for the month of November so far.

Dividend Stock Watch List: Lanny's December 2021 Edition

Many stocks are ridiculously expensive right now -- but not these three.

3 Pharma Stocks That Are Too Cheap to Ignore

GlaxoSmithKline

These stocks are unlikely to beat the market, but they're great for dividend income.

2 Cheap Pharma Stocks That Pay A Tidy Dividend

Don't expect it to follow the trajectory of a hot growth stock.

3 Things About Viatris That Smart Investors Know

PITTSBURGH, Nov. 18, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1, 2021. Chief Executive Officer Michael Goettler , President Rajiv Malik  and Chief Financial Officer Sanjeev Narula  will answer questions about the company at 7:30 a.m.

Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference

PITTSBURGH and BENGALURU, India, Nov. 16, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. today announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection

Viatris is a well-positioned manufacturer of legacy brand products, generics and biosimilars with a promising pipeline.

Viatris Is A Compelling Deep Value Pick

PITTSBURGH and NEW ORLEANS, Nov. 11, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a new kind of global healthcare company, today announced a $1 million donation that will have multi-year impact to SBP, a national U.S.-based not-for-profit organization dedicated to shrinking the time between disaster and recovery for low-income survivors. The partnership will focus primarily on SBP's Got Your Back Fund, an initiative that prioritizes post-disaster support for low-to-moderate income U.S. veterans.

Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities

Viatris Inc. (NASDAQ: VTRS) shares have advanced more than 5% after the company reported better than expected third-quarter results on Monday. Viatris's business continued to grow throughout the third fiscal quarter, and the company's management raised financial guidance for the full fiscal year during the third-quarter earnings call.

Should I buy Viatris shares after a strong Q3 report?

Viatris Inc. (VTRS) CEO Michael Goettler on Q3 2021 Results - Earnings Call Transcript

Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance.

News for Viatris Stock (VTRS)